IL-2 Delivery by Engineered Mesenchymal Stem Cells Re-invigorates CD8⁺ T Cells to Overcome Immunotherapy Resistance in Cancer

To determine if exogenous IL-2 in the tumor microenvironment could overcome immune checkpoint blockade resistance, researchers engineered MSCs to successfully deliver IL-2 mutein dimer to tumor-infiltrating lymphocytes.